A comparative review of the immunobiology of murine neuroblastoma and human neuroblastoma

Cancer

Volumn 79, Issue 9, 1997, Pages 1757-1766

  Ziegler, Moritz M ^a,b,d   Ishizu, Hiroyuki ^c   Nagabuchi, Eisuke ^c   Takada, Naoyuki ^c   Arya, Gajra ^a,b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HOKKAIDO UNIVERSITY   (Japan)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

human; immunobiology; murine; neuroblastoma; tumor

Indexed keywords

CATECHOLAMINE; CYTOKINE; HOMOVANILLIC ACID; IMMUNOSTIMULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NERVE CELL ADHESION MOLECULE; TUMOR VACCINE; VANILMANDELIC ACID;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CATECHOLAMINE METABOLISM; CYTOTOXIC LYMPHOCYTE; GANGLIONEUROMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOKINE ACTIVATED KILLER CELL; METASTASIS; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR REGRESSION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEUROBLASTOMA;

EID: 0030898194     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970501)79:9<1757::AID-CNCR18>3.0.CO;2-X     Document Type: Article

References (76)

1. Ziegler MM, Naito H, McCarrick JW III, Topolian SL, Ricci JL, Fox A, et al. C-1300 murine neuroblastoma: a suitable animal mode of human disease. In: Brooks BF. Malignant Tumors of Childhood. Austin: University of Texas Press, 1986:114-26.
2. Chatten J, Shimada H, Sather HN, Wong KY, Siegel SE, Hammond GD. Prognostic value of histopathology in advanced neuroblastoma: a report from the Children's Cancer Study Group. Hum Pathol 1988;19:1187-98.
3. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JS, Shuster JJ, et al. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas: a clinico-pathologic study of 211 cases from the Pediatric Oncology Group. Cancer 1992;69:2197-211.
4. Hayes FA, Mauer AM. Cell kinetics and chemotherapy in neuroblastoma. J Natl Cancer Inst 1976;57:697-9.
5. Fitzgibbon MC, Tormey WP. Paediatric reference ranges for urinary catecholamines/metabolites and their reference in neuroblastoma diagnosis. Ann Clin Biochem 1994;31:1-11.
6. Carlsen NL. How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br J Cancer 1990;61:441-6.
7. Beckwith JB, Perrin EV. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. Am J Pathol 1963;43:1089-104.
8. Squire R, Fowler CL, Brooks SP, Rich GA, Cooney DR. The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma. J Pediatr Surg 1990;25:381-6.
9. Knudson AG Jr., Meadows AT. Regression of neuroblastoma IV-S: a genetic hypothesis. N Engl J Med 1980;302:1254-6.
10. Nakagawara A, Sasazuki T, Akiyama H, Kawakami K, Kuwano A, et al. N-myc oncogene and stage IV-S neuroblastoma: preliminary observations on ten cases.Cancer 1990;65:1960-7.
11. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993; 53:2044-50.
12. Pritchard J, Wickman JA. Why does stage IV-S neuroblastoma regress spontaneously? Lancet 1994;344:869-70.
13. Naito H, Ziegler MM, Tsou KC. Rational selection of adjuvant chemotherapy after cytoreduction surgery for murine neuroblastoma. Cancer Res 1985;45:3554-60.
14. Ishizu H, Arya G, Bove KE, Ziegler MM. Immune-mediated regression of 'metastatic' neuroblastoma in the liver. J Pediatr Surg 1994;29:155-60.
15. Pons G, O'Dea RF, Mirkin BL. Biological characterization of the C-1300 murine neuroblastoma: an in vivo neural crest tumor model. Cancer Res 1982;42:3719-23.
16. Ruben GD, Ziegler MM. Influence of primary tumor site on lymphocyte anti-tumor activity. J Pediatr Surg 1983;18:30-3.
17. Choi SH, Lim TS, Hwant EH. Influence of primary tumor site on host anti-tumor immunity. Yonsei Med J 1992;33:258-64.
18. Schengrund CL, Repman MA, Sheffler BA. Response of mature mice to challenge with neuroblastoma after inoculation with neuroblastoma cells as neonates. Cancer Lett 1982; 17:229-35.
19. Sakamoto I, Kawakatsu H, Kidowaki T, Matumura T, Sugimoto T, Sawada T. Experimental study of the maternal effects on tumor immunity of infant mice with C-1300 mouse neuroblastoma. J Pediatr Surg 1988;23:350-3.
20. Brodeur GM. Patterns and significance of genetic changes in neuroblastomas. In: Pretlow TGJ, Pretlow TP. Biochemical and molecular aspects of selected cancers. San Diego: Academic Press, 1991:251.
21. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54.
22. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma associated with unfavorable histology and N-myc amplification. Am J Pathol 1993;143:1543-50.
23. Figarella-Branger DF, Durbee PL, Rougan GN. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. Cancer Res 1990;50:6364-70.
24. Kowitz A, Kadman G, Verschueren H, Remels L, DeBaetselier PD, Hubbe M, et al. Expression of L1 cell adhesion molecule is associated with lymphoma growth and metastasis. Clin Exp Metastasis 1993;11:419-29.
25. Linnemann D, Raz A, Bock E. Differential expression of cell adhesion molecules in variants of K1735 melanoma cells differing in metastatic capacity. Int J Cancer 1989;43:709-12.
26. Nauts HC. Immunotherapy of cancer: the pioneer work of Coley. Giovinasso, Italy: International Symposium on Endotoxin, 1986.
27. Koop CE, Kiesewetter WB, Horn RC Jr. Neuroblastoma in childhood: survival after major surgical insult to tumor. Surgery 1955;38:272-8.
28. Everson TC, Cole WH. Spontaneous regression of cancer. Philadelphia: Saunders, 1966:88-163.
29. Koop CE. Abdominal tumors in infants and children. Arch Dis Child 1960;35:1-16.
30. Hellstrom I, Hellstrom KE, Bill AH, Pierce GE, Yang JPS. Studies on cellular immunity to human neuroblastoma cells. Int J Cancer 1970;6:172-88.
31. Hellstrom KE, Hellstrom I. Immunity to neuroblastomas and melanomas. Ann Res Med 1972;23:19-38.
32. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
33. Akeson R, Herschman H. Neural antigens of morphologically differentiated neuroblastoma cells. Nature 1974; 249:620-3.
34. Terman DS, Stewart I, Tovel A, Kirch D. Localization of neuroblastoma in vivo with tumor specific antibodies. Cancer Res 1975;35:17616.
35. 2 microglobulin on human neuroblastoma cell lines. J Immunol 1983;130:2471-8.
36. 2-microglobulin expression of neuronal cell lines can be modulated by interferon. Proc Natl Acad Sci U S A 1984;81:6476-80.
37. Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 1985;135:242-6.
38. Alvarado CS, Findley HW, Chan WC, Hnath RS, Abdel-Mageed A, Paris RC, et al. Natural killer cells in children with malignant solid tumors: effect of recombinant interferon-2 and interleukin-2 on natural killer cell function against tumor cell lines. Cancer 1989;63:83-9.
39. Valteau D, Scott V, Carcelain G, Hartmann O, Excudier B, Hercend T, et al. T-cell receptor repertoire in neuroblastoma patients. Cancer Res 1996;56:362-9.
40. Seeger RC, Siegel SE, Sidell N. Neuroblastoma: clinical perspectives, monoclonal antibodies, and retinoic acid. Ann Int Med 1982;97:873-84.
41. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985;45:2642-9.
42. Saito M, Yu RK, Cheung NK. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Comm 1985;127:1-7.
43. Frantz CN, Duerst RE, Ryan DH, Gelsomino NL, Constine LS, Gregory PK. Anti-neuroblastoma monoclonal antibodies which do not bind to bone marrow cells. Prog Clin Biol Res 1985;175:485-99.
44. Gross N, Beck D, Carrel S, Munoz M. Highly selective recognition of human neuroblastoma cells by mouse monoclonal antibody to a cytoplasmic antigen. Cancer Res 1986;46:2988-94.
45. Mujoo K, Spiro RC, Reisfeld RA. Characterization of a unique glycoprotein antigen expressed on the surface of human neuroblastoma cells. J Biol Chem 1986;261:10299-305.
46. Honsi KCJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci U S A 1986; 83:7893-7.
47. Kawashima I, Tada N, Fujimori T, Tai T. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro. J Biochem 1990;108:109-15.
48. Mayer P, Handgretinger R, Bruchelt G, Schaber B, Rassner G, Fierbeck G. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB3.6 and 14.G2a. Melanoma Res 1994;4:101-6.
49. Cheung NK, Cheung IY, Carete A, Yeh SJ, Kushner B, Bonilla MA, et al. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res 1994;54:2228-33.
50. Cheung NK. Immunotherapy: neuroblastoma as a model. Pediatr Clin North Am 1991;38:425-41.
51. Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunol 1994;15:29-37.
52. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (NCAM/CD56). J Immunol 1991;146:4421-6.
53. Melino G, Vernole P, Annicchiarico-Petruzzelli M, Stephanou A, Colantoni A, Knight RA, et al. An inducible cell line (Natasha), from a neuroblastoma patient with circulating HRS-positive blasts, expressing neurohormones. Anti-cancer Res 1992;12:1199-206.
54. Evans A, Lampson L, Main E, Zier K, Ikegaki N, Tortaglione M, et al. Effects of gamma interferon on the NK and tumor cells of children with neuroblastoma. Proc AACR 1988; 29:416.
55. Ribeiro RC, Rill D, Roberson PK, Furman WL, Pratt CB, Brenner M, et al. Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer 1993;72:623-8.
56. Favrot MC, Michon J, Floret D, Cochat C, Negrier S, Mathiot C, et al. Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation. Pediatr Hematol Oncol 1990; 7:275-84.
57. Negrier S, Michon J, Floret D, Bouffet E, Gentet JC, Philip I, et al. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 1991;9:1363-70.
58. Cheung NK, Burch L, Kushner BH, Munn DH. Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: a phase II trial. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC. Advances in neuroblastoma research. New York: Wiley-Liss, Inc., 1991:395-400.
59. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992;35:199-204.
60. Yu AL, Gillies SD, Reisfeld RA. Phase I clinical trial of ch14.18 in patients with refractory neuroblastoma. Proc Am Soc Clin Oncol 1991;10:318.
61. Choi SH, Reynolds JV, Ziegler MM. Systematic analysis of the immunoregulation of murine neuroblastoma. J Pediatr Surg 1989;24:15-20.
62. Reynolds JV, Shou J, Choi H, Sigal R, Ziegler MM, Daly JM. The influence of natural killer cells in neuroblastoma. Arch Surg 1989;124:235-8.
63. Sigal RK, Reynolds JV, Markman JF, Shou J, Evantosh E, Ziegler MM, et al. Upregulation of MHC class I: effect on growth and LAK sensitivity of neuroblastoma. Surg Forum 1988;39:527-75.
64. Sigal RK, Lieberman MD, Reynolds JV, Williams N, Ziegler MM, Daly JM. Tumor immunization: improved results after vaccine modified with recombinant interferon gamma. Arch Surg 1990;25:308-12.
65. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T, et al. Exogenous expression of mouse interferon gamma cDNA in mouse C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci U S A 1989;86:9456-60.
66. Katsanis E, Bausero MA, Panoskaltsis-Mortari A, Dancisak BB, Xu Z, et al. Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. Cancer Gene Ther 1996;3:75-82.
67. Gopas J, Itzhaky D, Segev Y, Salzberg S, Trink B, Isakov N, et al. Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells. Cancer Immunol Immunother 1992;34:313-20.
68. Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, et al. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther 1995;2:39-46.
69. Katsanis E, Orchard PJ, Bausero MA, Garden KB, McIvor RS, Blazar BR. Interleukin-2 gene transer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother Emphasis Tumor Immunol 1994;15:81-90.
70. Goldman A, Gordon I, Pritchard J, Kemshead J. A monoclonal antibody, UJ13A, used for radioimmunolocalization of neuroblastoma in an animal model and patients. Prog Exp Tumor Res 1985;29:85-92.
71. Katsanis E, Bausero MA, Xu H, Orchard PJ, Xu Z, McIvor RS, et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2 dependent killing. Cancer Immunol Immunother 1994;38:135-41.
72. Nagabuchi E, Kunikane H, Krishan A, Arya G, Ziegler MM. In vitro invasiveness in comparison with the expression of MHC-1 antigen in murine neuroblastoma. Proc Am Assoc Cancer Res 1994;35:62.
73. Nagabuchi E, Itoh K, Krishan A, Kunikane H, Ziegler MM. Expression of the L1 molecule in highly metastatic murine neuroblastoma. Proc Am Assoc Cancer Res 1995;36:62.
74. Ziegler MM, Vega A, Koop CE. Electrocoagulation-induced immunity: an explanation for regression of neuroblastoma. J Pediatr Surg 1980;15:34-7.
75. McCormack CJ, Nairn JO, Rogers DW, Ziegler MM, Hinshaw JR. Beneficial effects following carbon dioxide laser excision on experimental neuroblastoma. J Pediatr Surg 1989;24:201-3.
76. Reynolds JV, Daly JM, Zhang S, Evantash E, Shou J, Sigal R, et al. Immunomodulatory mechanisms of arginine. Surgery 1988;104:142-51.